Hostname: page-component-76fb5796d-22dnz Total loading time: 0 Render date: 2024-04-25T08:26:07.331Z Has data issue: false hasContentIssue false
  • English
  • Français

The Neuroendocrinology of Posttraumatic Stress Disorder: New Directions

Published online by Cambridge University Press:  07 November 2014

Ann M. Rasmusson ,
Meena Vythilingam  and
Charles A. Morgan III
Get access Rights & Permissions [Opens in a new window]

Abstract

Studies of the hypothalamic-pituitary-adrenal (HPA ) axis in persons with posttraumatic stress disorder (PTSD) have produced variable findings. This review focuses on the factors likely to have affected the outcome of these studies, including population characteristics and experimental design. Also discussed is a possible role for the adrenal neurosteroid dehydroepiandrosterone (DHEA) as a mediator of HPA axis adaptation to extreme stress and the psychiatric symptoms associated with PTSD. The antiglucocorticoid properties of DHEA may contribute to an upregulation of HPA axis responses as well as mitigate possible deleterious effects of high cortisol levels on the brain in some PTSD subpopulations. The neuromodulatory effects of DHEA and its metabolite DHEAS at γ-arninobutyric acid and N-methyl-D-aspartate receptors in the brain may contribute to psychiatric symptoms associated with PTSD. The possible importance of other neurohormone systems in modulating HPA axis and symptom responses to traumatic stress is also discussed. Understanding the complex interactions of these stress-responsive neurosteroid and peptide systems may help explain the variability in patterns of HPA axis adaptation, brain changes, and psychiatric symptoms observed in PTSD and lead to better targeting of preventive and therapeutic interventions.

Type
Review Article
Information
CNS Spectrums , Volume 8 , Issue 9: Posttraumatic Stress Disorder , September 2003 , pp. 651 - 667
Copyright
Copyright © Cambridge University Press 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Mason, JW, Giller, EL, Kosten, TR, Ostroff, RB, Podd, L. Urinary-free cortisol levels in posttraumatic stress disorder patients. J Nerv Ment Dis. 1986;174;145–149.CrossRefGoogle ScholarPubMed
2.Yehuda, R, Southwick, SM, Nussbaum, G, et al.Low urinary cortisol excretion sin patients with posttraumatic stress disorder. J Nerv Ment Dis. 1990;178:366–369.CrossRefGoogle Scholar
3.Yehuda, R, Boisoneau, D, Mason, JW, Giller, EL. Relationship between lymphocyte glucocorticoid receptor number and urinary-free cortisol excretion in mood, anxiety, and psychotic disorder. Biol Psychiatry. 1993;34:18–25.CrossRefGoogle Scholar
4.Yehuda, R, Kahana, B, Binder-Brynes, K, et al.Low urinary cortisol excretion in Holocaust survivors with posttraumatic stress disorder. Am J Psychiatry. 1995;152:982–986.Google ScholarPubMed
5.Kosten, TR, Wahby, VS, Giller, E Jr, Mason, J. The dexamethasone suppression and thyrotropin-releasing hormone stimulation test in posttraumatic stress disorder. Biol Psychiatry. 1990;28:657–664.CrossRefGoogle ScholarPubMed
6.Baker, DG, West, SA, Nicholson, WE, et al.Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am J Psychiatry. 1999;156:986.CrossRefGoogle ScholarPubMed
7.Mason, JW, Wang, S, Yehuda, R, et al.Marked lability in urinary cortisol levels in subgroups of combat veterans with posttraumatic stress disorder during an intensive exposure treatment program. Psychosom Mad. 2002;64:238–246.CrossRefGoogle ScholarPubMed
8.Pitman, RK, Orr, SP. Twenty-four hour urinary cortisol and catecholamine excretion in combat-related posttraumatic stress disorder. Biol Psychiatry. 1990;27:245–247.CrossRefGoogle ScholarPubMed
9.Lemieux, AM, Coe, CL. Abuse-related posttraumatic stress disorder: evidence for chronic neuroendocrine activation in women. Psychsom Med. 1995;57:105–115.CrossRefGoogle ScholarPubMed
10.De Bellis, MD, Baum, AS, Birmaher, B, et al.A.E. Bennett Research Award. Developmental traumatology. Part I: Biological stress systems. Biol Psychiatry. 1999;45:1259–1270.CrossRefGoogle ScholarPubMed
11.Maes, M, Lin, A, Bonaccorso, S, et al.Increased 24-hour urinary cortisol excretion in patients with post-traumatic stress disorder and patients with major depression, but not in patients with fibromyalgia. Acta Psychiatr Scand. 1998;98:328–335.CrossRefGoogle Scholar
12.Rasmusson, AM, Lipschitz, DS, Wang, S, et al.Increased pituitary and adrenal reactivity in premenopausal women with posttraumatic stress disorder. Biol Psychiatry. 2001;50:965–977.CrossRefGoogle ScholarPubMed
13.Friedman, MJ, McDonagh-Coyle, AS, Jalowiec, JE, et al.Neurohormonal findings during treatment of women with PTSD due to childhood sexual abuse (CSA). Abstract presented at: Annual Meeting for the International Society for Traumatic Stress Studies; December 6-9, 2001; New Orleans, LA.Google Scholar
14.Beckham, JC, Kirby, AC, Feldman, ME, et al.Prevalence and correlates of heavy smoking in Vietnam veterans with chronic posttraumatic stress disorder. Addict Behav. 1997;22:637–647.CrossRefGoogle ScholarPubMed
15.Shalev, A, Bleich, A, Ursano, RJ. Posttraumatic stress disorder: somatic comorbidity and effort tolerance. Psychosomatics. 1990;31:197–203.CrossRefGoogle ScholarPubMed
16.Mason, JW, Wang, S, Yehuda, R, et al.Psychogenic lowering of urinary cortisol levels linked to increased emotional numbing and a shame-depressive syndrome in combat-related posttraumatic stress disorder. Psychosom Med. 2001;63:387–401.CrossRefGoogle Scholar
17.Aguilera, G. Regulation of pituitary ACTH secretion during chronic stress. Front Neuroendocrinol. 1994;15:321–350.CrossRefGoogle ScholarPubMed
18.Barden, N. Modulation of glucocorticoid receptor gene expression by antide-pressant drugs. Pharmacopsychiatry. 1996;29:12–22.CrossRefGoogle Scholar
19.Brady, LS, Gold, PW, Herkenham, M, Lynn, AB, Whitfield, HJ Jr.The antide-pressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res. 1992;572:117–125.CrossRefGoogle Scholar
20.Fuchs, JH, Barnes, C, Joyce, J, Medbak, S, Dinan, TG. Effects of antidepressant treatment on corticotropin-induced cortisol responses in patients with melancholic depression. Psychiatry Res. 1997;73:27–32.Google Scholar
21.Gold, PW, Licinio, J, Wong, ML, Chrousos, GP. Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Ann N Y Acad Sci. 1995;771:716–729.CrossRefGoogle ScholarPubMed
22.Thakore, JH, Barnes, C, Joyce, J, Medbak, S, Dinan, TG. Effects of antidepressant treatment on corticotropin-induced cortisol responses in patients with melancholic depression. Psychiatry Res. 1997;73:27–32.CrossRefGoogle ScholarPubMed
23.Rinne, T, de Kloet, ER, Wouters, L, et al.Fluvoxamine reduces responsiveness of HPA axis in adult female BPD patients with a history of sustained childhood abuse. Neuropsychopharmacology. 2003;28:126–132.CrossRefGoogle ScholarPubMed
24.Tandon, R, Mazzara, C, DeQuardo, J, et al.Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome. Biol Psychiatry. 1991;29:953–964.CrossRefGoogle ScholarPubMed
25.Vargas, MA, Bissette, G, Owens, MJ, Ehlers, CL, Nemeroff, CB. Effects of chronic ethanol and benzodiazepine treatment and withdrawal on corticotropin-releasing factor neural systems. Ann N Y Acad Sci. 1992;654:145–152.CrossRefGoogle ScholarPubMed
26.Ekman, AC, Vakkuri, O, Vuolteenaho, O, Leppaluoto, J. Delayed pro-opiomelanocortin activation after ethanol intake in man. Alcohol Clin Exp Res. 1994;18:1226–1229.CrossRefGoogle ScholarPubMed
27.Sarkola, T, Makisalo, H, Fukunaga, T, Eriksson, CJ. Acute effect of alcohol on estradiol, estrone, progesterone, prolactin, cortisol, and luteinizing hormone in premenopausal women. Alcohol Clin Exp Res. 1999;23:976–982.CrossRefGoogle ScholarPubMed
28.Yamada, Y, Tsuritani, I, Ishizaki, M, et al.Serum gamma-glutamyl transferase levels and blood pressure falls after alcohol moderation. Clin Exp Hypertens. 1997;19:249–268.CrossRefGoogle ScholarPubMed
29.Costa, A, Bono, G, Martignoni, E, et al.An assessment of hypothalamo-pituitary-adrenal axis functioning in non-depressed, early abstinent alcoholics. Psychoneuroeruiocrinology. 1996;21:263–275.CrossRefGoogle ScholarPubMed
30.Bernardy, NC, King, AC, Parsons, OA, Lovallo, WR. Altered cortisol response in sober alcoholics: an examination of contributing factors. Alcohol. 1996;13:493–498.CrossRefGoogle ScholarPubMed
31.Coiro, V, Vescovi, PP. Effect of cigarette smoking on ACTH/cortisol secretion in alcoholics after short- and medium-term abstinence. Alcohol Clin Exp Res. 1999;23:1515–1518.CrossRefGoogle Scholar
32.Sellini, M, Baccarini, S, Dimitriadis, E, Sartori, MP, Letizia, C. Effect of smoking on the hypophyseo-adrenal axis. [Italian] Medicina. 1989;9:194–196.Google ScholarPubMed
33.Spohr, U, Hengen, N, Harenberg, J, et al.The effects of nicotine on the circulation and metabolism after cigarette smoking with reference to the plasma levels of nicotine and COHb. [German] Munch Med Wochenschr. 1980;122(suppl 1):25–32.Google Scholar
34.Baron, JA, Comi, RJ, Cryns, V, Brinck-Johnsen, T, Mercer, NG. The effect of cigarette smoking on adrenal cortical hormones. J Pharmacol Exp Ther. 1995;272:151–155.Google ScholarPubMed
35.Eliasson, M, Hagg, E, Lundblad, D, Karlsson, R, Bucht, E. Influence of smoking and snuff use on electrolytes, adrenal and calcium regulating hormones. Acta Endocrinol. 1993;128:35–40.Google ScholarPubMed
36.Kirschbaum, C, Scherer, G, Strasburger, CJ. Pituitary and adrenal hormone responses to pharmacological, physical, and psychological stimulation in habitual smokers and nonsmokers. Clin Investig. 1994;72:804–810.CrossRefGoogle ScholarPubMed
37.Krishnan-Sarin, S, Rosen, MI, O'Malley, SS. Naloxone challenge in smokers. Preliminary evidence of an opioid component in nicotine dependence. Arch Gen Psychiatry. 1999;56:663–668.CrossRefGoogle ScholarPubMed
38.Witchel, SF, Lee, PA, Suda-Hartman, M, Trucco, M, Hoffman, EP. Evidence for a heterozygote advantage in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. 1997;82:2097–2101.Google ScholarPubMed
39.Witchel, SF, Lee, PA. Identification of heterozygotic carriers of 21-hydroxylase deficiency: sensitivity of ACTH stimulation tests. Am J Med Genet. 1998;76:337–342.3.0.CO;2-M>CrossRefGoogle ScholarPubMed
40.Merke, DP, Keil, ME, Negro, PJ, Gold, P, Chrousos, GP. 21-hydroxylase deficient carriers reset their hypothalamic-pituitary axis to normalize cortisol production: potential relation to mood changes leading to a selective advantage. Endocrine Society Meeting Poster Abstr. 1999: PI-659.Google Scholar
41.Yehuda, R, Halligan, SL, Bierer, LM. Cortisol levels in adult offspring of Holocaust survivors: relation to PTSD symptom severity in the parent and child. Psychoneuroendocrinology. 2002;27:171–180.CrossRefGoogle ScholarPubMed
42.Smith, MA, Davidson, J, Ritchie, JC, et al.The corticotropin-releasing hormone test in patients with posttraumatic stress disorder. Biol Psychiatry. 1989;26:349–355.CrossRefGoogle ScholarPubMed
43.Gold, PW, Licinio, J, Wong, M-L, Chrousos, GP. Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Ann N Y Acad Sci. 1995;771:716–729.CrossRefGoogle ScholarPubMed
44.Arborelius, L, Owens, MJ, Plotsky, PM, Nemeroff, CB. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol. 1999;160:1–12.CrossRefGoogle ScholarPubMed
45.Liberzon, I, Abelson, JL, Flagel, SB, Raz, J, Young, EA. Neuroendocrine and psychophysiologic responses in PTSD: a symptom provocation study. Neuropsychopharmacology. 1999;21:40–50.CrossRefGoogle ScholarPubMed
46.Kaufman, J, Birmaher, B, Perel, J, et al.The corticotropin-releasing hormone challenge in depressed abused, depressed nonabused, and normal control children. Biol Psychiatry. 1997;42:669–679.CrossRefGoogle ScholarPubMed
47.Heim, C, Newport, DJ, Bonsall, R, Miller, AH, Nemeroff, CB. Altered pituitary-adrenal axis responses to provocative challenge tests in adult survivors of childhood abuse. Am J Psychiatry. 2001;158:575–581.CrossRefGoogle ScholarPubMed
48.Heim, C, Newport, DJ, Heit, S, et al.Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA. 2000;284:592–597.CrossRefGoogle ScholarPubMed
49.Heim, C, Newport, DJ, Wagner, D, et al.The role of early adverse experience and adulthood stress in the prediction of neuroendocrine stress reactivity in women: a multiple regression analysis. Depress Anxiety. 2002;15:117–125.CrossRefGoogle ScholarPubMed
50.Rasmusson, AM, Zimolo, Z, Vasek, J, et al.Increased adrenal DHEA release in premenopausal women with PTSD. Paper presented at: Annual Meeting of the Society for Neuroscience; November 4-9, 2000; New Orleans, LA.Google Scholar
51.Spivak, B, Maayan, R, Kotler, M, et al.Elevated circulatory level of GABAA-antagonistic neurosteroids in patients with combat-related post-traumatic stress disorder. Psychol Med. 2000;30:1227–1231.CrossRefGoogle Scholar
52.Sondergaard, HP, Hansson, LO, Theorell, T. Elevated blood levels of dehydroepiandrosterone sulphate vary with symptom load in posttraumatic stress disorder: findings from a longitudinal study of refugees in Sweden. Psychother Psychosom. 2002;71:298–303.CrossRefGoogle ScholarPubMed
53.Van Haarst, AD, Oitzl, MS, Workel, JO, De Kloet, ER. Chronic brain glucocorticoid receptor blockade enhances the rise in circadian and stress-induced pituitary-adrenal activity. Endocrinology. 1996;137:4935–4943.CrossRefGoogle ScholarPubMed
54.Blauer, KL, Poth, M, Rogers, W, Bernton, EW. Dehydroepiandrosterone antagonizes the suppressive effects of dexamethasone on lymphocyte proliferation. Endocrinobgy. 1991;129:3174–3179.CrossRefGoogle ScholarPubMed
55.Morfin, R, Starka, L. Neurosteroid 7-hydroxylation products in the brain. Int Rev Neurobiol. 2001;46:79–95.CrossRefGoogle ScholarPubMed
56.Bertagna, X, Escourolle, H, Pinquier, JL, et al.Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation. J Clin Endocrinol Metab. 1994;78:375–380.Google ScholarPubMed
57.Kudielka, BM, Hellhammer, J, Hellhammer, DH, et al.Sex differences in endocrine and psychological responses to psychosocial stress in healthy elderly subjects and the impact of a 2-week dehydroepiandrosterone treatment. J Clin Endocrinol Metab. 1998;83:1756–1761.Google ScholarPubMed
58.Baulieu, EE, Robel, P. Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) as neuroactive neurosteroids. Proc Natl Acad Sci U S A. 1998;95:4089–4091.CrossRefGoogle ScholarPubMed
59.Yehuda, R, Levengood, RA, Schmeidler, J, et al.Increased pituitary activation following metyrapone administration in post-traumatic stress disorder. Psychoneuroendrocrinology. 1996;21:1–16.CrossRefGoogle ScholarPubMed
60.Orth, DN, Kovacs, WJ. The adrenal cortex. In: Willson, JD, Foster, DW, Kronenherg, HM, Larsen, Pr, eds. The Williams Textbook of Endocrinology. 9th ed. Philadelphia, Pa: WB Saunders & Co.; 1998:525.Google Scholar
61.Kanter, ED, Wilkinson, CW, Radant, AD, et al.Glucocorticoid feedback sensitivity and adrenocortical responsivemess in posttraumatic stress disorder. Biol Psychiatry. 2001;50:238–245.CrossRefGoogle ScholarPubMed
62.Matta, SG, Valentine, JD, Sharp, BM. Nicotine activates NPY and catecholaminergic neurons in brainstem regions involved in ACTH secretion. Brain Res. 1997;759:259–269.CrossRefGoogle ScholarPubMed
63.Pickworth, WB, Fant, RV. Endocrine effects of nicotine administration, tobacco and other drug withdrawal in humans. Psychoneuroendocrinology. 1998;23:131–141.CrossRefGoogle ScholarPubMed
64.Cam, GR, Bassett, JR. Effect of prolonged exposure to nicotine and stress on the pituitary-adrenocortical response; the possibility of cross-adaptation. Pharmacol Biochem Behav. 1984;20:221–226.CrossRefGoogle ScholarPubMed
65.Neslter, JE. Advances in understanding the regulation and biologic actions of dehydroepiandrosterone. Curr Op Endocrinol Diabetes. 1996;3:202–211.Google Scholar
66.Hornsby, PJ. Biosynthesis of DHEAS by the human adrenal cortex and its age-related decline. Ann N Y Acad Sci. 1995;774:29–46.CrossRefGoogle ScholarPubMed
67.Compagnone, NA, Mellon, SH. Neurosteroids: biosynthesis and function of these novel neuromodulators. Front Neuroendocrinol. 2000;21:1–56.CrossRefGoogle ScholarPubMed
68.Rose, KA, Stapleton, G, Dott, K, et al.Cyp7b, a novel brain cytochrome P450, catalyzes the synthesis of neurosteroids 7alpha-hydroxy dehy-droepiandrosterone and 7alpha-hydroxy pregnenolone. Proc Natl Acad Sci U S A. 1997;94:4925–4930.CrossRefGoogle ScholarPubMed
69.Kimonides, VG, Khatibi, NH, Svendsen, CN, Sofroniew, MV, Herbert, J. Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEAS) protect hippocampal neurons against excitatory amino acid-induced neurotoxicity. Proc Natl Acad Sci U S A. 1998;95:1852–1857.CrossRefGoogle ScholarPubMed
70.Bastianetto, S, Ramassamy, C, Poirier, J, Quirion, R. Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage. Brain Res Mol Brain Res. 1999;66:35–41.CrossRefGoogle ScholarPubMed
71.Kaminska, M, Harris, J, Gijsbers, K, Dubrovsky, B. Dehydroepiandrosterone sulfate (DHEAS) counteracts decremental effects of corticosterone on dentate gyrus LTP. Implications for depression. Brain Res Bull. 2000;52:229–234.CrossRefGoogle ScholarPubMed
72.Karishma, KK, Herbert, J. Dehydroepiandrosterone (DHEA) stimulates neurogenesis in the hippocampus of the rat, promotes survival of newly formed neurons and prevents corticosterone-induced suppression. Eur J Neurosci. 2002;16:445–453.CrossRefGoogle ScholarPubMed
73.Zhang, L, Li, B, Ma, W, et al.Dehydroepiandrosterone (DHEA) and its sulfated derivative (DHEAS) regulate apoptosis during neurogenesis by triggering the Akt signaling pathway in opposing ways. Brain Res Mol Brain Res. 2002;98:58–66.CrossRefGoogle ScholarPubMed
74.Hull, AM. Neuroimaging findings in post-traumatic stress disorder. Systematic review. Br J Psychiatry. 2002;181:102–110.Google ScholarPubMed
75.Gilbertson, MW, Shenton, ME, Ciszewski, A, et al.Smaller hippocampal volume predicts pathologic vulnerability to psychological trauma. Nat Neurosci. 2002;5:1242–1247.CrossRefGoogle ScholarPubMed
76.Bonne, O, Brandes, D, Gilboa, A, et al.Longitudinal MRI study of hippocampal volume in trauma survivors with PTSD. Am J Psychiatry. 2001;158:1248–1251.CrossRefGoogle ScholarPubMed
77.De Bellis, MD, Hall, J, Boring, AM, Frustaci, K, Moritz, G. A pilot longitudinal study of hippocampal volumes in pediatric maltreatment-related posttraumatic stress disorder. Biol Psychiatry. 2001;50:305–309.CrossRefGoogle ScholarPubMed
78.Fennema-Notestine, C, Stein, MB, Kennedy, CM, Archibald, SL, Jernigan, TL. Brain morphometry in female victims of intimate partner violence with and without posttraumatic stress disorder. Biol Psychiatry. 2002;52:1089–1101.CrossRefGoogle ScholarPubMed
79.Morgan, CA. Predicting performance: what we can learn from psychobiological studies of humans participating in highly stressful military training. Paper presented at Annual Meeting of the Society for Biological Psychiatry; May 3-5, 2001; New Orleans, La.Google Scholar
80.Grundemann, D, Schechinger, B, Rappold, GA, Schomig, E. Molecular identification of the cortisone-sensitive extraneuronal catecholamine transporter. Nat Neurosci. 1998;1:349–351.CrossRefGoogle Scholar
81.Bremner, JD, Innis, RB, Ng, CK, et al.Positron emission tomography measurement of cerebral metabolic correlates of yohimbine administration in combat-related posttraumatic stress disorder. Arch Gen Psychiatry. 1997;54:246–254.CrossRefGoogle ScholarPubMed
82.Rasmusson, AM, Schultz, R, Aikins, D, Southwick, SM, Arnsten, A. Impaired performance of frontal lobe-dependent neuropsychological tasks in combatrelated PTSD. Paper presented at: Annual Meeting of American College of Neuropsychopharmacology; December 8–12, 2002; San Juan, Puerto Rico.Google Scholar
83.Wolkowitz, OM, Reus, VI, Keebler, A, et al.Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry. 1999;156:646–649.CrossRefGoogle ScholarPubMed
84.Strous, R, Maayan, R, Lapidus, R, et al.Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry. 2003;60:133–141.CrossRefGoogle ScholarPubMed
85.McEwen, BS. Allostasis and allostatic load: implications for neuropsychopharmacology. Neuropsychopharmocology. 2000;22:108–124.CrossRefGoogle ScholarPubMed
86.Morgan, CA III, Rasmusson, AM, Wang, S, et al.Neuropeptide-Y, cortisol and subjective distress in humans exposed to acute stress: replication and extension of previous report. Biol Psychiatry. 2002;52:136–142.CrossRefGoogle ScholarPubMed
87.Rasmusson, AM, Hauger, RL, Morgan, CA, et al.Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD. Biol Psychiatry. 2000;47:526–539.CrossRefGoogle ScholarPubMed
88.Antonijevic, IA, Murck, H, Bohlhalter, S, et al.Neuropeptide Y promotes sleep and inhibits ACTH and cortisol release in young men. Neuropharmocology. 2000;39:1474–1481.CrossRefGoogle ScholarPubMed
89.Barbaccia, ML, Serra, M, Purdy, RH, Biggio, G. Stress and neuroactive steroids. Int Rev Neurobiol. 2001;46:243–272.CrossRefGoogle ScholarPubMed
90.Wang, S, Mason, J. Elevations of serum T3 levels and their association with symptoms in World War II veterans with conbat-related posttraumatic stress disorder: replication of findings in Vietnam combat veterans. Psychosom Med. 1999;61:131–138.CrossRefGoogle ScholarPubMed
91.Cohen, H, Benjamin, J, Kaplan, Z, Kotler, M. Administration of high-dose ketoconazole, an inhibitor of steroid synthesis, prevents posttraumatic anxiety in an animal model. Eur Neuropsychopharmocol. 2000;10:429–435.CrossRefGoogle ScholarPubMed
92.Prasad, A, Imamura, M, Prasad, C. Dehydroepiandrosterone decreases behavioral despair in high- but not low-anxiety rats. Physiol Behav. 1997;62:1053–1057.CrossRefGoogle Scholar
93.Kroboth, PD, Amico, JA, Stone, RA, et al.Influence of DHEA administration on 24-hour cortisol concentrations. J Clin Psychopharmacol. 2003;23:96–99.CrossRefGoogle ScholarPubMed